\n “This is good news for Nebraska,” said Sen. Ricketts. “It has the potential to bring over 100 new jobs to our state. This investment further underscores BD’s ongoing commitment to keep critical manufacturing in states like Nebraska. I appreciate BD’s long-standing partnership with the Cornhusker State.”<\/p>\n The BD Neopak\u2122 Glass Prefillable Syringe platform is purpose-built to meet the complex and evolving needs of biologics and combination\u00a0products\u00a0development. Available in 1 mL and 2.25 mL formats, the BD Neopak\u2122 Glass Prefillable Syringe supports a wide range of formulation requirements, including high viscosity, drug-container compatibility, and integration with delivery devices. It is designed for seamless integration with autoinjectors, enabling flexible, patient-centric drug delivery in both clinical and at-home settings.<\/p>\n “As demand for biologics and GLP-1s accelerates, BD is strengthening its American manufacturing footprint to support U.S.-based drug delivery innovation and supply chain resiliency,”\u00a0said Patrick Jeukenne,\u00a0worldwide president\u00a0of BD\u00a0Pharmaceutical Systems.\u00a0“This investment in Nebraska, advances our long-term growth strategy and reflects our commitment to partnering with biopharmaceutical innovators as they bring advanced therapies to patients who require next-generation drug delivery solutions.”<\/p>\n Strategic Investments in Columbus, Nebraska This announcement builds on BD’s recent investment of more than $35 million to expand prefilled flush syringe manufacturing in Columbus, which will add approximately 50 new jobs and strengthen the supply of critical medical devices to health care providers across the U.S. BD Columbus has been a strategic site within BD’s global manufacturing network for more than 75 years and is home to part of the company’s vertically integrated cannula manufacturing operations, including design and production. As the\u00a0largest medical device manufacturer in the United States, these investments are part of BD’s commitment to invest more than $2.5 billion in U.S. manufacturing capabilities over the next five years.<\/p>\n Strengthening U.S. Supply Chain Resilience As the global leader in biologics drug delivery, BD continues to invest in innovation and infrastructure to meet current needs and ensure that patients everywhere can benefit from the therapies of tomorrow.\u00a0<\/p>\n About\u00a0BD Additional Quotes for Media Use U.S. Congressman Mike Flood: Nebraska Governor Jim Pillen: Contacts:<\/p>\n <\/p>\n Media<\/p>\n Investors<\/p>\n Fallon McLoughlin Adam Reiffe\u00a0<\/p>\n Vice President, Investor Relations<\/p>\n 201.847.6927\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n Adam.Reiffe@bd.com<\/a>\u00a0 <\/p>\n \u00a0<\/p>\n \n SOURCE BD (Becton, Dickinson and Company)<\/p>\n
\n ![\"BD](\"https:\/\/www.newsbeep.com\/ca\/wp-content\/uploads\/2026\/01\/BD.jpg\" "\\"BD")
\n <\/a>\n <\/p>\n
BD is investing $100 million to establish BD Neopak\u2122 Glass Prefillable Syringe production at its Columbus site, with supply expected to begin in mid-2026. This investment will also support additional line upgrades and capacity improvements across the site, ensuring BD can meet growing global demand for advanced injectable solutions. In addition, BD is investing $10 million to enhance cannula manufacturing capabilities at the site, and together these investments will add approximately 120 new jobs.<\/p>\n
This expansion underscores the company’s commitment to building a more resilient and responsive pharmaceutical supply chain in the United States. By localizing production of the BD Neopak\u2122 Glass Prefillable Syringe platform, BD is helping to ensure continuity, scalability, and speed to market for life-changing injectable therapies \u2013 especially as demand rises for biologics and combination products used to treat chronic and high-burden diseases.<\/p>\n
BD is\u00a0one of\u00a0the\u00a0largest global medical\u00a0technology\u00a0companies in the\u00a0world\u00a0and is advancing\u00a0the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in\u00a0virtually\u00a0every\u00a0country\u00a0and\u00a0partners\u00a0with\u00a0organizations\u00a0around\u00a0the\u00a0world to\u00a0address\u00a0some\u00a0of the\u00a0most\u00a0challenging\u00a0global\u00a0health issues.\u00a0By\u00a0working in\u00a0close\u00a0collaboration\u00a0with\u00a0customers,\u00a0BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com<\/a>\u00a0or connect with us on LinkedIn at www.linkedin.com\/company\/bd1\/<\/a>, X (formerly Twitter) @BDandCo<\/a>\u00a0or Instagram @becton_dickinson<\/a><\/p>\n
U.S. Senator Deb Fischer:
“It’s encouraging to see companies like BD continue to invest and expand in Nebraska, which will strengthen our economy and provide good-paying jobs for hundreds of hard-working Nebraskans.”<\/p>\n
“Once again, BD is stepping up and creating more great opportunities in Columbus, Nebraska. Americans want to see more manufacturers choose to make things right here at home, and BD is doing just that. Congratulations to BD and the City of Columbus on this announcement, and I look forward to seeing BD continue to grow in the years to come.”<\/p>\n
“This is another perfect example of a company with global reach producing high value, cutting edge products at its plant right here in Nebraska. We can compete with anyone in the world and we are the best at what we do because of our people. The announcement of this expansion for BD is exciting news.”\u00a0<\/p>\n
Director, Public Relations
201.258.0361\u00a0
Fallon.Mcloughlin@bd.com<\/a> \u00a0<\/p>\n
\n ![\"BD](\"https:\/\/www.newsbeep.com\/ca\/wp-content\/uploads\/2025\/07\/BD_Logo.jpg\" "\\"BD"){kind=logo}
\n <\/a>\n <\/p>\n